Lilly Scores Another Obesity Win; Viking, Novo Stocks Slump - Investor's Business Daily

Eli Lilly (LLY) said Tuesday it will soon ask global regulators to approve its weight-loss pill, orforglipron, following a third successful Phase 3 study in patients with type 2 diabetes and obesity.…